September 16, 2010

FDA Psychopharmacologic Drugs Advisory Committee Meeting Materials About Vivitrol for Opioid Dependence Treatment

The U.S. Food and Drug Administration's Psychopharmacologic Drugs Advisory Committee met to consider clinical evidence for the use of Vivitrol, naltrexone in an extended-release injectable suspension, as a treatment for treating opioid dependence treatment. Vivitrol is a non-addictive compound delivered in a monthly injection. The Advisory Committee's recommendation will be considered by the FDA during its review of the supplemental New Drug Application (sNDA) that Alkermes has submitted for Vivitrol.